A5000475357- Cancer Genomics and Diagnostics
- PARP inhibition in cancer therapy
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Lung Cancer Treatments and Mutations
- Multiple and Secondary Primary Cancers
- Radiation Therapy and Dosimetry
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Research Studies
- Ferroptosis and cancer prognosis
- Metal-Catalyzed Oxygenation Mechanisms
- Glutathione Transferases and Polymorphisms
- Colorectal Cancer Treatments and Studies
- Redox biology and oxidative stress
- Genetic factors in colorectal cancer
- Neuroendocrine Tumor Research Advances
- Prostate Cancer Treatment and Research
- Lymphoma Diagnosis and Treatment
- DNA Repair Mechanisms
- BRCA gene mutations in cancer
Athens Medical Center
2020-2024
National and Kapodistrian University of Athens
2019
Predictive biomarkers are necessary for the identification of immunotherapy-responsive patients. Tumor mutation burden (TMB), as determined by next-generation sequencing (NGS), and PD-L1 expression, evaluated Immunohistochemistry (IHC), most frequently employed in clinical practice. In addition, microsatellite instability (MSI) was first biomarker to demonstrate immunotherapy efficacy irrespective type tumor possesses a high predictive value. However, its limited use across types limits...
Abstract Background Tumor molecular profile analysis by Next Generation Sequencing technology is currently widely applied in clinical practice and has enabled the detection of predictive biomarkers response to targeted treatment. In parallel with therapies, immunotherapies are also evolving, revolutionizing cancer therapy, Programmed Death-ligand 1 (PD-L1), Microsatellite instability (MSI), Mutational Burden (TMB) being employed most commonly. Methods present study, tumor was performed using...
Several tumor types have been efficiently treated with PARP inhibitors (PARPis), which are now approved for the treatment of ovarian, breast, prostate, and pancreatic cancers. The BRCA1/2 genes mutations in many additional involved HR pathway may be responsible HRD phenomenon. aim present study was to investigate association between genomic loss heterozygosity (gLOH) alterations 513 targeted immuno-oncology therapies 406 samples using an NGS assay. In addition, %gLOHs 24 were calculated...
Abstract AIM Endocrine therapy (ET) represents the first line treatment for patients with ER+, HER2- breast cancer, however disease progression is observed in many cases. PIK3CA and ESR1 are most encountered mutated genes that have been associated targeted molecular treatment, as well resistance to Therapy. Liquid biopsy a non-invasive procedure, can provide “real-time” monitoring of response treatment. The aim this study determine mutation rate selected cohort 200 Greek cancer patients,...
Several tumor types have been efficiently treated with PARPis, which are now approved for the treatment of ovarian, breast, prostate, and pancreatic cancer. The BRCA1/2 genes mutations in many additional involved HR pathway may be responsible HRD phenomenon. In present study, an NGS assay was used to analyze 513 associated targeted immuno-oncology therapies 406 samples. addition, %gLOH values 24 samples were also calculated using Affymetrix technology compare results obtained by two...
Despite ongoing oncological advances, pancreatic ductal adenocarcinoma (PDAC) continues to have an extremely poor prognosis with limited targeted and immunotherapeutic options. Its genomic background has not been fully characterized yet in large-scale populations all over the world. Methods: Replicating a recent study from China, we collected tissue samples consecutive Greek patients pathologically-confirmed metastatic/unresectable PDAC retrospectively investigated their landscape using next...
e17056 Background: Prostate cancer (PCa) represents the second most common malignancy in males, characterized by a high level of clinical and molecular heterogeneity. Eventually, many patients develop metastatic Castration Resistant Cancer (mCRPC). mCRPC refers to prostate that has spread beyond gland is associated with increased morbidity mortality. Next Generation Sequencing (NGS) led identification genomic alterations may represent actionable targets therapeutic potential mCRPC. Such can...
e15169 Background: Several tumor types have been efficiently treated with PARP inhibitors, a class of proteins involved in DNA repair pathway, which are approved for the treatment ovarian, breast, prostate, and pancreatic cancer. The BRCA1/2 genes essential homologous recombination, tumors carry this type mutations appear to defective recombination pathway as result loss second non mutated allele tumor. However, both epigenetic changes many other HR including Fanconi anemia ΑRID1A, ATM,...
Background: Despite ongoing oncological advances, pancreatic ductal adenocarcinoma (PDAC) keeps an extremely poor prognosis with limited targeted and immunotherapeutic options. Its genomic background has not been fully characterized yet in large-scale populations all over the world. Methods: Replicating a recent study from China, we collected tissue samples consecutive Greek patients pathologically-confirmed metastatic/unresectable PDAC retrospectively investigated their landscape using...
Abstract Background : Tumor molecular profile is of great importance for the detection biomarkers response to targeted treatment due increased availability, with concomitant reduction cost, Next Generation Sequencing technology (NGS). In parallel therapies’, immunotherapies are also evolving, revolutionizing cancer therapy, Programmed Death-ligand 1 (PD-L1), Microsatellite Instability (MSI), and Mutational Burden (TMB) analysis being employed most commonly. Methods present study, a 161 gene...
Abstract Background: Comprehensive tumor analysis by Next Generation Sequencing (NGS) is imperative for targeted and immunotherapy related biomarkers’ in metastatic breast cancer enabling personalization of treatment these patients. In parallel with therapies, immunotherapies are also evolving, revolutionizing therapy. Thus, biomarkers such as. Microsatellite Instability (MSI), Tumor Mutational Burden (TMB) commonly employed NGS due to their correlation Immune Checkpoint inhibitors...